2025 연구자 정보 (22 / 654)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Yamaguchi, Tetsuo (Yamaguchi, T) |
제1저자 |
Dongguk Univ, Dept Energy & Mat Engn, Seoul 04620, South Korea Kwansei Gakuin Univ, Dept Appl Chem Environm, Sanda, Hyogo 6691330, Japan |
|
|
[JCR상위 1.6%] Stabilization of chemically flexible indigo dye against photodegradation under solvent condition through intercalation into layered double hydroxide | SCIE | 1.6 |
CHEMISTRY, PHYSICAL MATERIALS SCIENCE, MULTIDISCIPLINARY MINERALOGY |
jaemin.oh@dongguk.edu | |
|
Al-Ahmadie, Hikmat (Al-Ahmadie, H) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Antonuzzo, Lorenzo (Antonuzzo, L) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Atduev, Vagif (Atduev, V) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Baek, John (Baek, J) |
제1저자 | BeamWorks Inc, Daegu, South Korea |
|
|
[JCR상위 1.7%] Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study. [JCR상위 91.3%] Clinical Application of Artificial Intelligence in Breast Ultrasound |
SCIE ESCI |
1.7 |
ONCOLOGY RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING |
greenoaktree9@gmail.com | |
|
Barroso-Sousa, Romualdo (Barroso-Sousa, R) |
T-6405-2019 BARROSO-SOUSA, ROMUALDO |
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Bin Lee, Yun (Lee, YB) |
Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B [JCR상위 1.0%] Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial |
SCIE | 1.0 | GASTROENTEROLOGY & HEPATOLOGY |
pindra@empal.com limys@amc.seoul.kr |
||
|
Cao, Ke (Cao, K) |
Brii Biosci Beijing Co Ltd, Beijing, Peoples R China |
|
|
[JCR상위 1.7%] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | jia_jd@ccmu.edu.cn | ||
|
Casalnuovo, Monica (Casalnuovo, M) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Catto, James W. F. (Catto, JWF) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Chae, Yee Soo (Chae, YS) |
Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Hematol Oncol, Daegu, South Korea Kyungpook Natl Univ, Sch Med, Dept Hematooncol, Daegu, South Korea |
|
|
[JCR상위 1.7%] Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study. [JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. [JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. [JCR상위 38.0%] Comparative analysis of the lumboperitoneal shunt versus ventriculoperitoneal shunt for leptomeningeal metastasis-associated hydrocephalus in non-small cell lung cancer [JCR상위 1.7%] Role of EMP2 in triple-negative breast cancer. [JCR상위 1.7%] Predicting high-risk group according to Oncotype DX recurrence score using dynamic contrast-enhanced breast MR with temporal radiomic features. |
SCIE | 1.7 |
ONCOLOGY CLINICAL NEUROLOGY SURGERY |
kiss798@gmail.com | ||
|
Chang, Chao-Hsiang (Chang, CH) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Chaudhari, Mukesh (Chaudhari, M) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Chen, Xiaofei (Chen, XF) |
Brii Biosci Beijing Co Ltd, Beijing, Peoples R China |
|
|
[JCR상위 1.7%] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | jia_jd@ccmu.edu.cn | ||
|
Cho, Eun Kyung (Cho, EK) |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY |
페이지 이동: